Zume
Search results
Zymergen was an American biotechnology company based in Emeryville, California. The company applies genomics and machine learning to research and design chemical producing genetically modified organisms. It claimed that its manufacturing process was safer and cheaper than traditional manufacturing, but was unable to demonstrate this.
Oct 19, 2022 · Today, we’re pleased to announce our completed acquisition of Zymergen. This is our largest acquisition to date! It’s expected to significantly enhance our platform by integrating strong automation and software capabilities as well as providing a wealth of experience across diverse biological engineering approaches.
Oct 13, 2021 · Zymergen’s stock tanked 69% that day, wiping out nearly $2.5 billion in market value. The disclosure was shocking for a company that had raised more than $1 billion in venture funding and $530...
Jul 25, 2022 · Zymergen, a synthetic biology company that shifted to drug discovery in January, has been acquired by Ginkgo Bioworks for $300 million. Ginkgo plans to integrate Zymergen's automation and software into its cell engineering platform and explore strategic alternatives for its drug pipeline.
Zymergen | 31,531 followers on LinkedIn. Zymergen is now a part of Ginkgo Bioworks!
Jul 25, 2022 · Ginkgo Bioworks acquired biotechnology firm Zymergen, the synthetic biology companies announced Monday morning, marking the final act in Zymergen’s dramatic and brisk fall from grace.
Aug 4, 2021 · On Tuesday afternoon, synthetic biology manufacturing company Zymergen said its cofounder and CEO would be stepping down immediately and that the company, which just went public in April, would...
